Access all of the content
Dr Catherine Shu (Columbia University Irving Medical Center, New York, NY, USA) discusses the findings of the CHRYSALIS-2 study, which supports the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer (NSCLC) and represents a chemotherapy-free regimen.
The abstract ‘Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2’ (Abstract: 9006) was presented at the ASCO annual meeting, 3-7 June 2022.
1. Could you tell us a little about combined therapy with amivantamab and Lazertinib, and the clinical evidence in support of its use?
2. What were the aims and design of the CHRYSALIS-2 study?
3. Which patients were included in cohort A and what were the efficacy findings in this study?
4. What was the safety profile of the combination and what is the importance of this combination?
Disclosures: Catherine A. Shu is a member of the advisory board for AstraZeneca, Mirati Therapeutics, Genentech and Janssen.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
Share this Video
Related Videos In Lung Cancer
Tarlatamab in pre-treated SCLC – DeLLphi-301 study: Luis Paz-Ares, EMSO 2023
The anticipated phase 2 data from the DeLLphi-301 study (NCT05060016), investigating the antitumor activity and safety of taralatamab administered at two doses in pre-treated small cell lung cancer (SCLC), were presented at this year’s EMSO meeting. To understand more about this investigational treatment and the results from the study we spoke with study investigator, Dr […]
Sunil Singhal, AACR 2023: Intraoperative molecular imaging as a tool in cancer surgery
Intraoperative molecular imaging enables surgeons to utilise a cancer specific fluorescent dye to improve cancer removal. In this touchONCOLOGY interview, we speak with Dr Sunil Singhal (University of Pennsylvania, Philadelphia, PA, USA) to discuss intraoperative molecular imaging, with focus on its application in lung cancer. The presentation entitled ‘Intraoperative molecular imaging of lung cancer: The […]
Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer
First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!